339 related articles for article (PubMed ID: 18292976)
21. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
22. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.
Turner DA; Khioe RFS; Shepstone L; Lenaghan E; Cooper C; Gittoes N; Harvey NC; Holland R; Howe A; McCloskey E; O'Neill TW; Torgerson D; Fordham R;
J Bone Miner Res; 2018 May; 33(5):845-851. PubMed ID: 29470854
[TBL] [Abstract][Full Text] [Related]
23. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
Kanis JA; McCloskey EV; Johansson H; Strom O; Borgstrom F; Oden A;
Osteoporos Int; 2008 Oct; 19(10):1395-408. PubMed ID: 18751937
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.
Nelson SD; Nelson RE; Cannon GW; Lawrence P; Battistone MJ; Grotzke M; Rosenblum Y; LaFleur J
Osteoporos Int; 2014 Dec; 25(12):2701-7. PubMed ID: 25037601
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of bone densitometry among Caucasian women and men without a prior fracture according to age and body weight.
Schousboe JT; Gourlay M; Fink HA; Taylor BC; Orwoll ES; Barrett-Connor E; Melton LJ; Cummings SR; Ensrud KE;
Osteoporos Int; 2013 Jan; 24(1):163-77. PubMed ID: 22349916
[TBL] [Abstract][Full Text] [Related]
26. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs.
Sander B; Elliot-Gibson V; Beaton DE; Bogoch ER; Maetzel A
J Bone Joint Surg Am; 2008 Jun; 90(6):1197-205. PubMed ID: 18519311
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Osteoporosis Interventions to Improve Quality of Care After Upper Extremity Fracture: Results From a Randomized Trial (C-STOP Trial).
Majumdar SR; Lier DA; McAlister FA; Johnson JA; Rowe BH; Beaupre LA
J Bone Miner Res; 2019 Jul; 34(7):1220-1228. PubMed ID: 30779861
[TBL] [Abstract][Full Text] [Related]
28. Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US.
Pike C; Birnbaum HG; Schiller M; Swallow E; Burge RT; Edgell ET
Osteoporos Int; 2011 Jan; 22(1):47-56. PubMed ID: 20490782
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of osteoporosis liaison service for secondary fracture prevention in postmenopausal osteoporosis patients with previous hip fracture in Japan.
Moriwaki K; Noto S
Osteoporos Int; 2017 Feb; 28(2):621-632. PubMed ID: 27699441
[TBL] [Abstract][Full Text] [Related]
30. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025.
Burge RT; King AB; Balda E; Worley D
Value Health; 2003; 6(5):574-83. PubMed ID: 14627064
[TBL] [Abstract][Full Text] [Related]
31. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
[TBL] [Abstract][Full Text] [Related]
32. The societal burden of osteoporosis in Sweden.
Borgström F; Sobocki P; Ström O; Jönsson B
Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Jansen JP; Gaugris S; Bergman G; Sen SS
Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Marques A; Lourenço Ó; Ortsäter G; Borgström F; Kanis JA; da Silva JA
Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Borgström F; Carlsson A; Sintonen H; Boonen S; Haentjens P; Burge R; Johnell O; Jönsson B; Kanis JA
Osteoporos Int; 2006; 17(7):996-1007. PubMed ID: 16570118
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of two inexpensive postfracture osteoporosis interventions: results of a randomized trial.
Majumdar SR; Lier DA; Leslie WD
J Clin Endocrinol Metab; 2013 May; 98(5):1991-2000. PubMed ID: 23596140
[TBL] [Abstract][Full Text] [Related]
37. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.
van Staa TP; Geusens P; Zhang B; Leufkens HG; Boonen A; Cooper C
Rheumatology (Oxford); 2007 Mar; 46(3):460-6. PubMed ID: 16899499
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
[TBL] [Abstract][Full Text] [Related]
39. Intervention thresholds for osteoporosis in the UK.
Kanis JA; Borgstrom F; Zethraeus N; Johnell O; Oden A; Jönsson B
Bone; 2005 Jan; 36(1):22-32. PubMed ID: 15663999
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of fracture prevention in established osteoporosis.
Jönsson B; Christiansen C; Johnell O; Hedbrandt J
Osteoporos Int; 1995 Mar; 5(2):136-42. PubMed ID: 7599450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
